Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.57 |
| ▸ | CASP7 | P55210 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PDE4A | P27815 | 1/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CFTR | P13569 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.53 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29847379 | 1.00 | CASP1 (0.57) | CASP1CASP7MAPK1PDE4APDE4B | |
| SCHEMBL7829144 | 0.98 | CASP1 (0.55) | CASP1CASP7MAPK1PDE4APDE4B | |
| SCHEMBL2783456 | 0.88 | MAPK1 (0.56) | CASP1CASP7MAPK1CYP2C19CYP1A2 | |
| SCHEMBL28410934 | 0.88 | CFTR (0.61) | CASP1CASP7MAPK1PDE4APDE4B | |
| SCHEMBL3012671 | 0.84 | MAPK1 (0.55) | CASP1CASP7MAPK1CYP2C19CYP1A2 | |
| SCHEMBL6579407 | 0.83 | CFTR (0.63) | CASP1CASP7MAPK1PDE4APDE4B | |
| SCHEMBL2783060 | 0.82 | ALDH1A1 (0.54) | CASP1CASP7MAPK1CYP2C19CYP1A2 | |
| SCHEMBL2783434 | 0.81 | OGFRL1 (0.48) | CASP1CASP7MAPK1OPRM1OPRK1 | |
| SCHEMBL2783058 | 0.81 | OGFRL1 (0.56) | CASP1CASP7MAPK1OPRM1OPRK1 | |
| SCHEMBL7951628 | 0.80 | L3MBTL1 (0.60) | CASP1CASP7MAPK1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113024475-B | Synthetic method of quinoxalinone compound | 宁夏大学 | 2022-08-09 | — | — | CN | claimed |
| CN-113024475-B | Synthetic method of quinoxalinone compound | 宁夏大学 | 2022-08-09 | — | — | CN | disclosed |
| CN-113024475-A | Synthetic method of quinoxalinone compound | 宁夏大学 | 2021-06-25 | — | — | CN | disclosed |
| EP-1048655-B1 | 1,2-DIHYDRO-2-OXOQUINOLINE DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2004-09-01 | — | — | EP | disclosed |
| US-6380384-B1 | ANXIOLYTIC AGENTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2002-04-30 | — | — | US | disclosed |
| US-20020049323-A1 | 1,2-Dihydro-2-oxoquinoline derivatives | NAKAZATO ATSURO (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6329525-B1 | 1,2-Dihydro-2-oxoquinoline derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6329389-B1 | HETEROCYCLIC AMINES AND DERIVATIVES, SOMATOSTATIN AND ANTIDIABETIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1070054-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2001-01-24 | — | — | EP | disclosed |
| EP-1048655-A1 | 1,2-DIHYDRO-2-OXOQUINOLINE DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2000-11-02 | — | — | EP | disclosed |
| WO-1999052875-A1 | AMINE COMPOUNDS, THEIR PRODUCTION AND THEIR USE AS SOMATOSTATIN RECEPTOR ANTAGONISTS OR AGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049323-A1 | 1,2-Dihydro-2-oxoquinoline derivatives | NR5A1, SRD5A1, SRD5A2 | CASP1 1160/4885CASP7 2260/4885MAPK1 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.